newsfilter
← Latest News
GlobeNewswire·

LEQEMBI® Pen (Subcutaneous Formulation of LEQEMBI®) Approved in Japan for the Treatment of Early Alzheimer’s Disease

TOKYO and CAMBRIDGE, Mass., Sept. 16, 2026 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. and Biogen Inc. (NASDAQ:BIIB), announced today that "LEQEMBI® Pen", the subcutaneous (SC) formulation of the anti-amyloid beta